PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance
PROCEPT BioRobotics (Nasdaq: PRCT) reported third-quarter 2025 results with Q3 revenue of $83.3M, up 43% year‑over‑year, and U.S. handpiece and consumables revenue of $44.4M (+50% YoY). The U.S. installed base reached 653 systems after adding 58 systems in the quarter. Gross margin expanded to 65%. Net loss was $21.4M and adjusted EBITDA loss improved to $7.4M in Q3. Cash and equivalents totaled $297.3M as of September 30, 2025. The company reiterated 2025 revenue guidance of about $325.5M and issued 2026 revenue guidance of $410–$430M (growth 26%–32%).
PROCEPT BioRobotics (Nasdaq: PRCT) ha riportato i risultati del terzo trimestre 2025 con fatturato del Q3 di 83,3 milioni di dollari, in aumento del 43% su base annua, e ricavi negli Stati Uniti di manico e consumabili pari a 44,4 milioni di dollari (+50% YoY). La base installata negli Stati Uniti ha raggiunto 653 sistemi dopo aver aggiunto 58 sistemi nel trimestre. Il margine lordo è salito al 65%. La perdita netta è stata di 21,4 milioni di dollari e la perdita di EBITDA rettificato è migliorata a 7,4 milioni di dollari nel trimestre. Le disponibilità liquide e equivalenti ammontavano a 297,3 milioni di dollari al 30 settembre 2025. L’azienda ha ribadito la guidance sui ricavi per il 2025 di circa 325,5 milioni di dollari e ha fornito la guidance sui ricavi per il 2026 di 410–430 milioni di dollari (crescita del 26%–32%).
PROCEPT BioRobotics (Nasdaq: PRCT) informó los resultados del tercer trimestre de 2025 con ingresos del Q3 de 83,3 millones de dólares, un 43% más que hace un año, y ingresos en EE. UU. por piezas de mano y consumibles de 44,4 millones de dólares (+50% interanual). La base instalada en EE. UU. alcanzó 653 sistemas tras añadir 58 sistemas en el trimestre. El margen bruto se expandió a 65%. La pérdida neta fue de 21,4 millones de dólares y la pérdida de EBITDA ajustado mejoró a 7,4 millones de dólares en el Q3. Las disponibilidades y equivalentes de efectivo totalizaron 297,3 millones de dólares al 30 de septiembre de 2025. La compañía reiteró la guía de ingresos para 2025 de aproximadamente 325,5 millones de dólares y emitió la guía de ingresos para 2026 de 410–430 millones de dólares (crecimiento del 26%–32%).
PROCEPT BioRobotics (나스닥: PRCT)가 2025년 3분기 실적을 발표했습니다. 3분기 매출은 8,330만 달러로 전년 동기 대비 43% 증가했고, 미국에서의 핸드피스 및 소모품 매출은 4,440만 달러(+40% 전년 대비 50%)였습니다. 미국 설치 기반은 분기에 58대가 추가되어 653대 시스템에 도달했습니다. 총이익률은 65%로 확대되었습니다. 순손실은 2,140만 달러였고 조정된 EBITDA 손실은 740만 달러로 개선되었습니다. 9월 30일 기준 현금 및 현금 등가물은 2억 9,730만 달러였습니다. 회사는 2025년 매출 가이던스를 약 3억 2,550만 달러로 재확인했고, 2026년 매출 가이던스로 4억 10–4억 30만 달러를 제시했습니다(성장률 26%–32%).
PROCEPT BioRobotics (Nasdaq: PRCT) a publié les résultats du troisième trimestre 2025 avec un chiffre d’affaires T3 de 83,3 millions de dollars, en hausse de 43% sur un an, et des revenus américains pour les pièces et consommables à 44,4 millions de dollars (+50% sur un an). La base installée américaine a atteint 653 systèmes après l’ajout de 58 systèmes au cours du trimestre.La marge brute s’est étendue à 65%. La perte nette s’est élevée à 21,4 millions de dollars et la perte d’EBITDA ajusté s’est améliorée à 7,4 millions de dollars au T3. Les liquidités et équivalents s’élevaient à 297,3 millions de dollars au 30 septembre 2025. L’entreprise a réaffirmé ses prévisions de revenus 2025 d’environ 325,5 millions de dollars et a publié ses prévisions 2026 de 410–430 millions de dollars (croissance de 26%–32%).
PROCEPT BioRobotics (Nasdaq: PRCT) meldete die Ergebnisse des dritten Quartals 2025 mit U3-Umsatz von 83,3 Mio. USD, ein Plus von 43% gegenüber dem Vorjahr, und US-Umsätze für Handstücke und Verbrauchsmaterialien von 44,4 Mio. USD (+50% YoY). Die installierte Basis in den USA erreichte 653 Systeme nach der Hinzufügung von 58 Systemen im Quartal. Die Bruttomarge stieg auf 65%. Der Nettolück betrug 21,4 Mio. USD und der bereinigte EBITDA-Verlust verbesserte sich auf 7,4 Mio. USD im Q3. Die Barbestände und Äquivalente betrugen 297,3 Mio. USD zum Stand 30. September 2025. Das Unternehmen bekräftigte seine Umsatzprognose für 2025 von ca. 325,5 Mio. USD und gab eine Umsatzprognose für 2026 von 410–430 Mio. USD bekannt (Wachstum 26%–32%).
PROCEPT BioRobotics (ناسداك: PRCT) أبلغت عن نتائج الربع الثالث من عام 2025 مع إيرادات الربع الثالث 83.3 مليون دولار، بارتفاع قدره 43% على أساس سنوي، وإيرادات الولايات المتحدة من رؤوس التشغيل واللوازم بقيمة 44.4 مليون دولار (+50% على أساس سنوي). قاعدة التثبيت في الولايات المتحدة بلغت 653 نظاماً بعد إضافة 58 نظاماً في الربع. هامش الربح الإجمالي توسع ليصل إلى 65%. الخسارة الصافية كانت 21.4 مليون دولار وتكاليف EBITDA المعدلة الخسارة تحسنت إلى 7.4 مليون دولار في الربع الثالث. اجمالي النقد وما يعادله بلغ 297.3 مليون دولار حتى 30 سبتمبر 2025. كررت الشركة توجيهات الإيرادات لعام 2025 نحو حوالي 325.5 مليون دولار وأصدرت توجيهات 2026 للإيرادات بقيمة 410–430 مليون دولار (نمو 26%–32%).
- Q3 revenue $83.3M (+43% YoY)
- U.S. handpiece revenue $44.4M (+50% YoY)
- Install base reached 653 systems after adding 58 systems
- Gross margin improved to 65%
- Net loss $21.4M in Q3
- Operating expenses $77.2M in Q3 (vs $59.3M prior year)
- Full‑year 2025 adjusted EBITDA loss guidance of $35.0M
Insights
Strong revenue growth and raised 2026 guidance, with continued operating losses and planned spending.
The company reported $83.3 million in Q3 revenue, a
Operating expenses rose to $77.2 million for the quarter from $59.3 million a year earlier, driven by commercial expansion, higher R&D and G&A spend, and one‑time leadership transition costs; net loss was $21.4 million and Adjusted EBITDA loss improved to $7.4 million. Cash and equivalents totaled
The company reiterated full‑year 2025 revenue guidance of approximately
Watch the cadence of system placements, recurring handpiece consumption, and whether gross margin improvements persist as the company scales; monitor quarterly operating expense trends against the stated
SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2025.
Recent Highlights
- Total revenue of
$83.3 million for the third quarter of 2025, an increase of43% compared to the prior year period in 2024 - U.S. handpiece and consumables revenue of
$44.4 million for the third quarter of 2025, an increase of50% compared to the prior year period in 2024 - The installed base in the U.S. increased by 58 robotic systems in the third quarter of 2025
- U.S. system and rental revenue of
$24.7 million for the third quarter of 2025, an increase of26% compared to the prior year period in 2024 - International revenue of
$9.4 million for the third quarter of 2025, an increase of53% compared to the prior year period in 2024 - Maintained fiscal year 2025 total revenue guidance of approximately
$325.5 million , an increase of45% compared to the prior year period in 2024 - Issued fiscal year 2026 total revenue guidance in the range of
$410 t o$430 million , representing growth of26% to32% compared to fiscal 2025 revenue guidance of$325.5 million .
“In my initial weeks as CEO, I am pleased to report we delivered a strong performance. We accelerated U.S. system placements, demonstrating strong demand for the HYDROS® Robotic System, and achieved
Third Quarter 2025 Financial Results
Total revenue for the third quarter of 2025 was
Gross margin for the third quarter 2025 was
Operating expenses in the third quarter of 2025 were
Net loss was
Cash, cash equivalents and restricted cash balances as of September 30, 2025, totaled
Full Year 2025 Financial Guidance
- The Company reiterates revenue for the full year 2025 to be approximately
$325.5 million , which represents45% growth over the Company’s prior year revenue. - The Company expects full year 2025 gross margins in the range of
64.0% to64.5% . The Company expects a gross margin headwind of approximately$2.0 million in the fourth quarter, attributable to tariff-related costs. - The Company reiterates full year 2025 total operating expense of approximately
$302.0 million . - The Company reiterates full year 2025 Adjusted EBITDA loss to be approximately (
$35.0) million .
Full Year 2026 Financial Guidance
- The Company projects revenue for the full year 2026 to be in the range of
$410 t o$430 million , which represents growth of26% to32% over the Company’s 2025 revenue guidance range.
Adjusted EBITDA is a financial measure that is not prepared in accordance with generally accepted accounting principles in the United States (GAAP). For more information about the Company’s use of non-GAAP financial measures, please see the section below titled “Use of Non-GAAP Financial Measures (Unaudited).
Webcast and Conference Call Information
PROCEPT BioRobotics will host a conference call to discuss the third quarter 2025 financial results on Tuesday, November 4, 2025, at 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by following one of the below links:
- Webcast link for interested listeners:
- Dial-in registration for sell-side research analysts:
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics’ mission is to revolutionize BPH treatment globally in partnership with urologists by delivering best-in-class robotic solutions that positively impact patients and drive value. PROCEPT BioRobotics manufactures the AQUABEAM® and HYDROS® Robotic Systems. The HYDROS® Robotic System is the only AI-Powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.
Use of Non-GAAP Financial Measures (Unaudited)
This press release references Adjusted EBITDA, a financial measure that is not prepared in accordance with generally accepted accounting principles in the United States (GAAP). The Company defines Adjusted EBITDA as earnings before interest expense, taxes, depreciation and amortization and stock-based compensation. Non-GAAP financial measures are not a substitute for or superior to measures of financial performance prepared in accordance with GAAP and should not be considered as an alternative to any other performance measures derived in accordance with GAAP.
The Company believes that presenting Adjusted EBITDA provides useful supplemental information to investors about the Company in understanding and evaluating its operating results, enhancing the overall understanding of its past performance and future prospects, and allowing for greater transparency with respect to key financial metrics used by its management in financial and operational decision making. However, there are a number of limitations related to the use of non-GAAP measures and their nearest GAAP equivalents. For example, other companies may calculate non-GAAP measures differently, or may use other measures to calculate their financial performance, and therefore any non-GAAP measures the Company uses may not be directly comparable to similarly titled measures of other companies.
Forward Looking Statements
This release contains forward‐looking statements within the meaning of federal securities laws, including with respect to the Company’s projected financial performance for full year 2025 and 2026, statements regarding the potential utilities, values, benefits and advantages of Aquablation therapy performed using PROCEPT BioRobotics’ products, including AquaBeam or Hydros Robotic Systems, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on the Company’s current expectations, estimates, and assumptions, valid only as of the date they are made, and subject to risks and uncertainties, some of which the Company is not currently aware. Forward-looking statements may include statements regarding financial guidance, market opportunity and penetration, clinical trial outcomes, the Company’s possible or assumed future results of operations, including descriptions of the Company’s revenues, gross margins, profitability, operating expenses, installed base growth, commercial momentum and overall business strategy. Forward‐looking statements should not be read as a guarantee of future performance or results and may not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. These forward‐looking statements are based on the Company’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward‐looking statements as a result of these risks and uncertainties. These risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the Company’s annual report on Form 10-K filed with the SEC on February 27, 2025, and amended on April 11, 2025, and subsequent quarterly reports on Form 10-Q. PROCEPT BioRobotics does not undertake any obligation to update forward‐looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward‐looking statements contained herein. These forward-looking statements should not be relied upon as representing PROCEPT BioRobotics’ views as of any date subsequent to the date of this press release.
Important Safety Information
All surgical treatments have inherent and associated side effects. For a list of potential side effects visit https://aquablation.com/safety-information/
Investor Contact:
Matt Bacso
VP, Investor Relations and Business Operations
m.bacso@procept-biorobotics.com
| PROCEPT BioRobotics Corporation CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited, in thousands, except per share data) | ||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenue | $ | 83,327 | $ | 58,370 | $ | 231,671 | $ | 156,262 | ||||||||
| Cost of sales | 29,321 | 21,459 | 81,758 | 62,835 | ||||||||||||
| Gross profit | 54,006 | 36,911 | 149,913 | 93,427 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 18,187 | 16,647 | 52,221 | 47,232 | ||||||||||||
| Selling, general and administrative | 59,011 | 42,691 | 170,510 | 123,099 | ||||||||||||
| Total operating expenses | 77,198 | 59,338 | 222,731 | 170,331 | ||||||||||||
| Loss from operations | (23,192 | ) | (22,427 | ) | (72,818 | ) | (76,904 | ) | ||||||||
| Interest expense | (919 | ) | (1,140 | ) | (2,692 | ) | (3,215 | ) | ||||||||
| Interest and other income, net | 2,700 | 2,593 | 9,783 | 7,562 | ||||||||||||
| Net loss | $ | (21,411 | ) | $ | (20,974 | ) | $ | (65,727 | ) | $ | (72,557 | ) | ||||
| Net loss per share, basic and diluted | $ | (0.38 | ) | $ | (0.40 | ) | $ | (1.19 | ) | $ | (1.41 | ) | ||||
| Weighted-average common shares used to | ||||||||||||||||
| Compute net loss per share attributable to | ||||||||||||||||
| Common shareholders, basic and diluted | 55,727 | 52,011 | 55,366 | 51,550 | ||||||||||||
| PROCEPT BioRobotics Corporation RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA (Unaudited, in thousands) | ||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Net loss | $ | (21,411 | ) | $ | (20,974 | ) | $ | (65,727 | ) | $ | (72,557 | ) | ||||
| Depreciation and amortization expense | 1,619 | 1,328 | 4,681 | 3,781 | ||||||||||||
| Stock-based compensation expense | 14,490 | 8,512 | 36,761 | 22,755 | ||||||||||||
| Interest (income) and interest expense, net | (2,093 | ) | (1,296 | ) | (6,913 | ) | (4,694 | ) | ||||||||
| Adjusted EBITDA | $ | (7,395 | ) | $ | (12,430 | ) | $ | (31,198 | ) | $ | (50,715 | ) | ||||
| PROCEPT BioRobotics Corporation RECONCILIATION OF GAAP NET LOSS TO ADJUSTED 2025 EBITDA Guidance (Unaudited, in thousands) | |||
| 2025 | |||
| Net loss | $ | (84,500 | ) |
| Depreciation and amortization expense | 6,800 | ||
| Stock-based compensation expense | 51,000 | ||
| Interest (income) and interest expense, net | (8,300 | ) | |
| Adjusted EBITDA | $ | (35,000 | ) |
PROCEPT BioRobotics Corporation
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited, in thousands)
| September 30, 2025 | December 31, 2024 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 294,281 | $ | 333,725 | ||||
| Accounts receivable, net | 84,504 | 83,496 | ||||||
| Inventory | 66,715 | 56,168 | ||||||
| Prepaid expenses and other current assets | 9,252 | 8,453 | ||||||
| Total current assets | 454,752 | 481,842 | ||||||
| Restricted cash, non-current | 3,038 | 3,038 | ||||||
| Property and equipment, net | 30,022 | 26,709 | ||||||
| Operating lease right-of-use assets, net | 17,904 | 18,941 | ||||||
| Intangible assets, net | 727 | 932 | ||||||
| Other assets | 5,098 | 2,555 | ||||||
| Total assets | $ | 511,541 | $ | 534,017 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 11,118 | $ | 10,032 | ||||
| Accrued compensation | 21,797 | 21,537 | ||||||
| Deferred revenue | 10,665 | 9,565 | ||||||
| Operating leases, current | 2,135 | 1,910 | ||||||
| Loan facility liability | — | 2,000 | ||||||
| Other current liabilities | 8,183 | 8,089 | ||||||
| Total current liabilities | 53,898 | 53,133 | ||||||
| Long-term debt | 51,566 | 51,472 | ||||||
| Operating leases, non-current | 25,225 | 26,868 | ||||||
| Other liabilities | 576 | 324 | ||||||
| Total liabilities | 131,265 | 131,797 | ||||||
| Stockholders’ equity: | ||||||||
| Additional paid-in capital | 991,945 | 948,091 | ||||||
| Accumulated other comprehensive gain | 42 | 114 | ||||||
| Accumulated deficit | (611,711 | ) | (545,985 | ) | ||||
| Total stockholders’ equity | 380,276 | 402,220 | ||||||
| Total liabilities and stockholders’ equity | $ | 511,541 | $ | 534,017 | ||||
PROCEPT BioRobotics Corporation
REVENUE BY TYPE AND GEOGRAPHY
(Unaudited, in thousands)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||
| U.S. | ||||||||||||
| System sales and rentals | $ | 24,747 | $ | 19,643 | $ | 65,400 | $ | 50,978 | ||||
| Handpieces and other consumables | 44,411 | 29,620 | 125,668 | 81,217 | ||||||||
| Service | 4,754 | 2,952 | 12,723 | 7,888 | ||||||||
| Total U.S. revenue | 73,912 | 52,215 | 203,791 | 140,083 | ||||||||
| Outside of U.S. | ||||||||||||
| System sales and rentals | 3,391 | 3,155 | 10,179 | 7,974 | ||||||||
| Handpieces and other consumables | 5,316 | 2,616 | 15,805 | 7,230 | ||||||||
| Service | 708 | 384 | 1,896 | 975 | ||||||||
| Total outside of U.S. revenue | 9,415 | 6,155 | 27,880 | 16,179 | ||||||||
| Total revenue | $ | 83,327 | $ | 58,370 | $ | 231,671 | $ | 156,262 | ||||
FAQ
What were PROCEPT BioRobotics (PRCT) Q3 2025 revenues and growth?
How much did PRCT generate from U.S. handpieces and consumables in Q3 2025?
What guidance did PROCEPT (PRCT) give for full‑year 2026 revenue on Nov 4, 2025?
What was PROCEPT’s Q3 2025 gross margin and adjusted EBITDA result?
How many HYDROS systems did PROCEPT (PRCT) have in the U.S. as of Sept 30, 2025?
